Comment on: Acute renal insufficiency during telavancin therapy in clinical practice

Manjunath P. Pai*

Albany College of Pharmacy and Health Sciences, Albany, NY 12208, USA

*Tel: +1-518-694-7146; Fax: +1-518-694-7062; E-mail: amit.pai@ccphs.edu

Keywords: telavancin, nephrotoxicity, vancomycin, obesity, dosing, acute kidney injury

Sir,

The recent article by Marcos et al.1 raises serious concerns about the current dosing recommendations for telavancin. The retrospective nature of their study (as the authors acknowledge) prevents direct attribution of the observed acute kidney injury (AKI) events to the use of telavancin.1 However, their findings regarding a link between high body mass index (BMI) and AKI are not entirely unexpected based on the population pharmacokinetics of telavancin.1 The currently recommended intravenous dose of telavancin is 10 mg/kg every 24 h in patients with a creatinine clearance (CLCR) >50 mL/min, and a reduction in dosage to 7.5 mg/kg every 24 h (30–50 mL/min) or 10 mg/kg every 48 h (10 to <30 mL/min).2 The dosage of telavancin is based on total body weight (TBW), but the CLCR value used to adjust its dose is estimated using the Cockcroft–Gault equation.3 Marcos et al.1 indicated that the telavancin dose was based on the estimated CLCR using the Cockcroft–Gault equation and TBW, which is inconsistent with the telavancin product label.1 This is an important distinction because TBW overestimates kidney function, while IBW underestimates kidney function in patients with a high BMI.4

As a specific example, overestimation of CLCR using TBW might have contributed to the use of a higher dosing tier of telavancin in Patient 5 (CLCR of 55 mL/min), as shown in Tables 1 and 2 of Marcos et al.1 A lower dose might have been selected if IBW had been used to estimate CLCR, as recommended in the product label.6 Unfortunately, this potential dosing error reflects the disharmonious approach to estimation of kidney function during drug development.1 This disharmony is evident with daptomycin, the dosage of which, like that of telavancin, is based on TBW but is adjusted for CLCR using the Cockcroft–Gault equation and TBW (not IBW).2 Similarly, automatic laboratory-reported glomerular filtration values should be used cautiously when defining telavancin doses until they have been validated. Beyond estimation of kidney function as a source of dosing error, a larger issue at hand is whether TBW is the right dosing scalar for telavancin in patients with a high BMI. Dosing on TBW implies that this scalar reduces inter-individual pharmacokinetic variability and leads to bioequivalent systemic exposures across the weight continuum. The population pharmacokinetic model that is the basis for telavancin dose justification actually suggests that this is not the case.2

The final population pharmacokinetic model for telavancin clearance (CL)=[0.286+0.00456×(CLCR)+0.0039×(TBW)]×sex+0.0847×ERAD, where CLCR is based on the Cockcroft–Gault equation and IBW, sex=1 for males and 0.907 for females, and ERAD is a flag for eradication (no eradication=0 and eradication=1).2 Population pharmacokinetic modelers will appreciate that TBW would likely not exist as an independent covariate of CL in this final model if CLCR estimated using the Cockcroft–Gault equation had actually used TBW instead of IBW. This is because IBW is often considered to be a weight dimension when in reality it is a height dimension transformed erroneously to weight.6 Despite these potential model development errors, the existing model for telavancin CL can still be used to simulate the AUC from 0 to 24 h (AUC0–24) of telavancin across the clinical weight spectrum based on the equation AUC=dose/CL.

Figure 1 illustrates the projected AUC0–24 values based on a dose of 10 mg/kg every 24 h and assumes fixed CLCR estimates of 51, 100 or 150 mL/min, using the above telavancin CL model. This projection is based on a random mean (coefficient of variation) normal weight distribution of 81 (27%) kg, with a random distribution for sex and eradication for 10000 subjects using StataSE version 11 (StataCorp, College Station, TX, USA). As shown (Figure 1), dosing on TBW leads to a steady rise in AUC0–24 as a function of TBW, implying non-bioequivalence across TBW. A mean (minimum, maximum) fractional change in telavancin AUC0–24 values of 3.47 (1.45, 5.91) is expected in patients with CLCR of 100 mL/min across the simulated weight range of 30–173 kg with current TBW-based dosing. Given that drug-induced AKI is likely to be related to systemic exposure, higher telavancin AUC0–24 values in larger patients should contribute to a higher risk of AKI. Post hoc analyses of two Phase 3 trials revealed the incidence of renal events to be 6.4% in patients with BMI <35 kg/m² and 2.3% in those with BMI >35 kg/m² treated with telavancin.5 This 2.8-fold difference in the incidence of renal events for telavancin between BMI groups was not observed with the use of vancomycin. As a result, the clinical documentation of high rates of AKI by Marcos et al.1 in obese individuals is consistent with the expected high telavancin exposure with weight-based dosing. Hence, a reappraisal of telavancin dosing in obese patients should be considered to reduce the risk of AKI without compromising its efficacy. Studies evaluating therapeutic drug monitoring of telavancin to define exposure–response (safety and efficacy) relationships in the clinical setting will aid with this reappraisal.

© The Author 2012. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com


**Letters to the Editor**

![Figure 1.](image-url)  

**Figure 1.** Projected mean (95% CI) AUC$_{0-24}$ with the use of a 10 mg/kg daily dose of telavancin in a simulated population with three estimates of CL$_{CR}$.

**Transparency declarations**

None to declare.

**References**


**J Antimicrob Chemother** 2012  
doi:10.1093/jac/dks103  
Advance Access publication 27 March 2012

**Acute renal insufficiency during telavancin therapy in clinical practice—authors’ response**

Luis A. Marcos*, Bernard C. Camins, David J. Ritchie, Ed Casabar and David K. Warren

---

**Transparency declarations**

B. C. C. and D. J. R. are on the speaker’s bureau of Astellas Pharma US, Inc. B. C. C. has received research support from Astellas Pharma US, Inc. D. K. W. has received research support from bioMérieux, Sage, Inc., Cubist Pharmaceuticals and 3M Healthcare, and has served as a consultant for 3M Healthcare and Bard, Inc. All other authors: none to declare.

**References**